Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS
Current Cardiology Reports, 06/06/2011
Rajan L et al. – Novel antiplatelet agents that act faster and have more consistent pharmacokinetics and higher potency are steadily emerging. Additionally, newer agents that target unique sites, such as the thrombin receptor on platelets, are being studied in large–scale clinical trials. Each of these new agents has the potential to extend net clinical benefits beyond those provided by aspirin and clopidogrel.